A PROCESS FOR CIS-SELECTIVE CATALYTIC HYDROGENATION OF CYCLOHEXYLIDENAMINES

摘要

ABSTRACT OF THE DISCLOSURE The present invention relates to a disubstituted maleimide compound of the formula [I] wherein Rsup1/sup is hydrogen or alkyl, Rsup2/sup is aryl, cycloalkyl or heterocyclic group, Rsup3/sup , Rsup5/sup , Rsup6/sup , Rsup7/sup and Rsup8/sup are hydrogen, halogen, hydroxyl group, amino, alkyl or alkoxy, and Rsup4/sup is W or Rsup4/sup and Rsup3/sup , or Rsup4/sup and Rsup5/sup jointly form a ring having a substituent W on the ring wherein W is - (CHsub2/sub )sub1/sub - (Y)subm/sub - (CHsub2/sub )subn/sub -Z, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing this compound, and a protein kinase C (PKC) β inhibitor. The compounds of the present invention selectively inhibit PKCβ, and can be safe and effective pharmaceutical or prophylactic agents against the diseases caused by PKC including diabetic complications.